55 unknown. 55 Phase 3, 19 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 55 | Unknown 55 |
| Phase 2 | 19 | Unknown 19 |
Follow Neurocognitive Disorders: new trials by email Literature Review of Neurocognitive Disorders trials Research Report on Neurocognitive Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cannabidiol's Role in Dementia Management Cannabidiol Oil - Dementia, Vascular, Dementia, Mixed | Phase 2 / Phase 3 | Unknown | Hospital Pengajar Universiti Putra Malaysia | 486 | 2024-09-01 | 2024-07-23 |
| Efficacy and Safety of NestaCell® in Huntington's Disease NestaCell® - Huntington Disease | Phase 3 | Unknown | Azidus Brasil | 120 | 2024-06-08 | 2023-10-24 |
| Effect of Intravenous Nalbuphine and Magnesium Sulfate on Emergence Agitation in Pediatric Nalbuphine Versus Magnesium Sulfate - Emergence Delirium | Phase 3 | Unknown | Assiut University | 105 | 2024-04-02 | 2024-03-12 |
| The Effect of Clonidine-enhanced Sedation on Delirium in Ventilated Critically Ill Patients Clonidine, SodiumChloride - Delirium | Phase 3 | Unknown | Deventer Ziekenhuis | 115 | 2024-01-01 | 2023-02-15 |
| IV Acetaminophen After Cardiac Surgery - PILOT acetaminophen - Delirium | Phase 3 | Unknown | McGill University Health Centre/Research Institute of the McGill University Health Centre | 900 | 2023-06-06 | 2024-02-28 |
| Implementation and Evaluation of Improved Access to Medical Imaging for Geriatric Patients of The Royal Ottawa Hospital [18F]FDG-PET Scan - Dementia, Cognitive Impairment | Phase 3 | Unknown | Tim Lau | 15 | 2023-05-01 | 2023-03-06 |
| Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients Silymarin, Placebo - Breast Cancer, Peripheral Neuropathy | Phase 2 / Phase 3 | Unknown | Tanta University | 56 | 2022-10-28 | 2022-10-26 |
| Ketamine to Treat Patients With Post-comatose Disorders of Consciousness Ketalar 50 MG/ML Injectable Solution, Placebo - Disorder of Consciousness | Phase 2 / Phase 3 | Unknown | University of Liege | 30 | 2022-05-01 | 2022-11-07 |
| Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease Nilotinib BE 84mg, Nilotinib BE 112 mg, Placebo - Alzheimer Disease | Phase 3 | Unknown | KeifeRx, LLC | 1275 | 2022-02-01 | 2021-12-03 |
| Sedation Efficacy of Dexmedetomidine Versus Midazolam in Critically Ill Ventilated Children Precedex, Midazolam - Mechanically Ventilated, Critically Ill Children | Phase 3 | Unknown | Douglas Fraser | 120 | 2021-06-08 | 2023-12-11 |
| Ketamine vs Midazolam on Cognitive Function in Elderly in Elective Surgery Three-Months Postoperatively (ketaminvsMDZ) ketamine sedation versus midazolam sedation - Cognitive Dysfunction | Phase 3 | Unknown | Universidad de Colima | 68 | 2021-01-24 | 2021-01-26 |
| A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease PM012, PM012 Placebo, Donepezil - Mild Alzheimer Disease | Phase 2 / Phase 3 | Unknown | Mediforum Ltd., Co. | 312 | 2020-11-27 | 2023-04-18 |
| Multimodal Biomarkers for Diagnosis and Prognosis in VCI amyloid PET - Vascular Cognitive Impairment, Alzheimer Disease | Phase 3 | Unknown | National Taiwan University Hospital | 120 | 2020-09-03 | 2020-10-27 |
| Dapagliflozin Effect in Cognitive Impairment in Stroke Trial Dapagliflozin 10mg Tab, Statins (Cardiovascular Agents), Platelet Antiaggregant - Stroke, Ischemic, Mild Cognitive Impairment | Phase 2 / Phase 3 | Unknown | Jaime Daniel Mondragon | 270 | 2020-08-01 | 2022-10-04 |
| Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients. Cellavita-HD - Huntington Disease | Phase 2 / Phase 3 | Unknown | Azidus Brasil | 35 | 2020-02-10 | 2022-10-28 |
| Study on Clinical Effectiveness of L-Oxiracetam Injection Test group: L-oxiracetam Injection, Control group: Oxiracetam Injection, Placebo group: Placebo Injection - Craniocerebral Injury | Phase 3 | Unknown | Nanjing Yoko Biomedical Co., Ltd. | 591 | 2019-09-30 | 2024-02-15 |
| Noradrenergic Add-on Therapy With Guanfacine Guanfacine, Placebo - Alzheimer Disease | Phase 3 | Unknown | Imperial College London | 148 | 2019-01-04 | 2024-05-13 |
| Multimodal Biomarkers for Diagnosis and Prognosis in CAA 1. amyloid PET；2. T807 PET - Cerebral Amyloid Angiopathy, Intracranial Hemorrhages | Phase 3 | Unknown | National Taiwan University Hospital | 240 | 2018-09-27 | 2021-03-12 |
| Donepezil Attenuate Postoperative Cognitive Dysfunction Donepezil, Placebo - Osteoarthritis, Femoral Head Necrosis | Phase 3 | Unknown | RenJi Hospital | 550 | 2018-09-01 | 2020-01-30 |
| 18F-Flutemetamol and Plaque Vulnerability 18F-Flutemetamol PET/MRI - Atherosclerosis | Phase 2 / Phase 3 | Unknown | Maastricht University Medical Center | 25 | 2018-02-01 | 2019-07-11 |
Showing 20 of 55. Sign in to see all of them.
Alzheimer Disease (19) · Cognitive Dysfunction (16) · Dementia (7) · Delirium (6) · Emergence Delirium (5) · Dementia, Vascular (4) · Cognition Disorders (3) · Huntington Disease (3) · Consciousness Disorders (2) · Lewy Body Disease (2) · Postoperative Cognitive Complications (2) · Schizophrenia (2) · Stroke (2) · AIDS Dementia Complex (1) · Affective Symptoms (1)
Mental Disorders (55) · Nervous System Diseases (44) · Brain Diseases (30) · Central Nervous System Diseases (30) · Neurodegenerative Diseases (23) · Cognition Disorders (21) · Dementia (21) · Pathological Conditions, Signs and Symptoms (21) · Tauopathies (19) · Neurologic Manifestations (16) · Signs and Symptoms (16) · Neurobehavioral Manifestations (14) · Pathologic Processes (11) · Confusion (10)
Donepezil (4) · Dexmedetomidine (2) · Memantine (2) · Methylphenidate (2) · Transcranial Direct Current Stimulation (2) · Acetaminophen (1) · Acupuncture Therapy (1) · Aspirin (1) · Atorvastatin (1) · Bexarotene (1) · Biguanides (1) · Bromocriptine (1) · Caloric Restriction (1) · Cannabidiol (1) · Cardiovascular Agents (1)
Bellus Health Inc. - a GSK company (3) · National Taiwan University Hospital (3) · Azidus Brasil (2) · Federal University of Paraíba (2) · RenJi Hospital (2) · University Hospital, Angers (2) · Amsterdam UMC, location VUmc (1) · Assiut University (1) · Azienda Ospedaliero-Universitaria di Parma (1) · Banner Health (1) · Beersheva Mental Health Center (1) · Brasilia University Hospital (1) · Charite University, Berlin, Germany (1) · Chiang Mai University (1) · Deventer Ziekenhuis (1)
China (7) · United States (6) · Brazil (5) · Canada (5) · Netherlands (5) · France (4) · Germany (4) · United Kingdom (4) · Taiwan (3) · Australia (2) · Belgium (2) · Italy (2) · Mexico (2) · South Korea (2) · Spain (2)
Alessandra Dei Cas, MD (1) · Ardis A Moe, M.D. (1) · Arthur J Dalton, PhD (1) · Bertram Scheller, MD (1) · Brandon M Kucher, PhD, MD (1) · Carolyn Liebsack, BSN (1) · Chen-Chung Liu, MD, PhD (1) · Chuanhan Zhang, MD. (1) · Cornelia Reininger, MD PhD (1) · D.William Molloy, MB, MRCPI, FRCPC (1) · Diansan Su, M.D., Ph.D. (1) · Douglas D Fraser, MD., PhD (1) · Dr. Tanyong Pipanmekaporn, MD (1)
PMID 18303488, PMID 20146803, PMID 20204386, PMID 23040716, PMID 24257429, PMID 25788770, PMID 26420269, PMID 27027720, PMID 27965560, PMID 28095900, PMID 28950419, PMID 29016744, PMID 29371333, PMID 29446769, PMID 29559423, PMID 29573529, PMID 30336844, PMID 30336869, PMID 30450044, PMID 31236801, PMID 31248555, PMID 31535829, PMID 31910895, PMID 32115470, PMID 32144994, PMID 32178931, PMID 32317958, PMID 32352644, PMID 32559474, PMID 32854852, PMID 33030307, PMID 33189083, PMID 33282811, PMID 33883015, PMID 33894597, PMID 34813630, PMID 35915506, PMID 37859768, PMID 38975302, PMID 40049590, PMID 41381424, PMID 42032764
2015 (1), R01AG016381 (1)